Comparison of recombinant and synthetically formed monoclonal antibody-β-lactamase conjugates for anticancer prodrug activation

Bioconjugate Chemistry

Volumn 10, Issue 6, 1999, Pages 1084-1089

  Kerr, David E ^a,c   Vrudhula, Vivekananda M ^a   Svensson, Håkan P ^a,d   Siemers, Nathan O ^a   Senter, Peter D ^a,b  

^a BRISTOL MYERS SQUIBB   (United States)

^b SEATTLE GENETICS INC   (United States)

^c BioControl Systems Inc   (United States)

^d CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; ANTIGENS; BIOLOGICAL ORGANS; CELL CULTURE; CELLS; RECOMBINANT PROTEINS; TUMORS;

CROSS-LINKING REAGENTS; ENTEROBACTER CLOACAE; FAB' FRAGMENT; LUNG CARCINOMA; MAXIMUM TOLERATED DOSE; PRODRUG ACTIVATION; PRODRUGS; RENAL CELL CARCINOMA; TUMOR MODELS; Β-LACTAMASE;

MONOCLONAL ANTIBODIES;

EID: 0033230497     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc990075w     Document Type: Article

References (30)

1. Senter, P. D., and Svensson, H. P. (1996) A summary of monoclonal antibody-enzyme/prodrug combinations. Adv. Drug Delivery Rev. 22, 341-349.
2. Niculescu-Duvaz, I., and Springer, C. J. (1995) Antibody-directed enzyme prodrug therapy (ADEPT): A targeting strategy in cancer chemotherapy. Curr. Med. Chem. 2, 687-706.
3. Melton, R. G., and Sherwood, R. F. (1996) Antibody-enzyme conjugates for cancer therapy. J. Natl. Cancer Inst. 88, 153-165.
4. Bagshawe, K. D. and Begent, R. H. J. (1996) First clinical experiment with ADEPT. Adv. Drug Delivery Rev. 22, 365-367.
5. Vrudhula, V. M., Svensson, H. P., Kennedy, K. A, Senter, P. D., and Wallace, P. M. (1993) Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Bioconjugate Chem. 4, 334-340.
6. Vrudhula, V. M., Svensson, H. P., and Senter, P. D. (1995) Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-β-lactamase conjugates. J. Med. Chem. 38, 1380-1385.
7. Svensson, H. P., Vrudhula, V. M., Emsweiler, J. E., MacMaster, J. F., Cosand, W. L., Senter, P. D., and Wallace, P. M. (1995) In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Cancer Res. 55, 2357-2365.
8. Kerr, D. K., Li, Z., Siemers, N. O., Senter, P. D., and Vrudhula, V. M. (1998) Development and activities of a new melphalan prodrug designed for tumor-selective activation. Bioconjugate Chem. 9, 255-259.
9. Kerr, D. E., Schreiber, G. J., Vrudhula, V. M., Svensson, H. P., Hellstrom I., Hellstrom, K. E., and Senter, P. D. (1995) Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res. 55, 3558-3563.
10. Svensson, H. P., Frank, I. S., Berry, K. K., Vrudhula, V. M., and Senter, P. D. (1998) Therapeutic effects of monoclonal antibody-β-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma. J. Med. Chem. 41, 1507-1512.
11. Siemers, N. O., Kerr, D. E., Yarnold, S., Stebbins, M., Vrudhula, V. M., Hellström, I., Hellström, K. E., and Senter, P. D. (1997) Construction, expression, and activities of L49-sFv-β-lactamase, a single chain antibody fusion protein for anticancer prodrug activation. Bioconjugate Chem. 8, 510-519.
12. Meyer, D. L., Jungheim, L. N., Law, K. L., Mikolajczyk, S. D., Shepherd, T. A., Mackensen, D. G., Briggs, S. L., and Starling, J. J. (1993) Site-specific prodrug activation by antibody-β-lactamase conjugates: regressions and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 53, 3956-3963.
13. Meyer, D. L., Law, L. L., Payne, J. K., Mikolajczyk, S. D., Zarrinmayeh, H., Jungheim, L. N., Kling, J. K., Shepherd, T. A., and Starling, J. J. (1995). Site-specific prodrug activation by antibody-β-lactamase conjugates: preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis. Bioconjugate Chem. 6, 440-446.
14. Woodbury, R. G., Brown, J. P., Yeh, M. Y., Hellström I., and Hellström K. E. (1980) Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc. Natl. Acad. Sci. U.S.A. 77, 2183-2187.
15. Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H. H., Schuermann, M., and Seemann, G. (1992) Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer 65, 234-238.
16. Haisma, H. J., Sernee, M. F., Hooijberg, E., Brakenhoff, R. H., Meulen-Muileman, I. H., and Pinedo, H. M. (1998) Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood 92, 184-190.
17. Rodrigues, M. L., Presta, L. G., Kotts, C. E., Wirth, C., Mordenti, J., Osaka, G., Wong, W. L., Nuijens, A., Blackburn, B., and Carter, P. (1995) Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55, 63-70.
18. Rodrigues, M. L., Carter, P., Wirth, C., Mullins, S., Lee, A., and Blackburn, B. K. (1995) Synthesis and β-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem. Biol. 2, 223-227.
19. Goshorn, S. C., Svensson, H. P., Kerr, D. E., Sommerville, J. E., Senter, P. D., and Fell, H. P. (1993) Genetic construction, expression, and characterization of a single-chain anti-carcinoma antibody fused to β-lactamase. Cancer Res. 53, 2123-2127.
20. Svensson, H. P., Wallace, P. M., and Senter, P. D. (1994) Synthesis and characterization of monoclonal antibody-β-lactamase conjugates. Bioconjugate Chem. 5, 262-267.
21. Siemers, N. O., Yelton, D. E., Bajorath, J., and Senter, P. D. (1996) Modifying the specificity and activity of the Enterobacter cloacae P99 β-lactamase by mutagenesis within an M13 phage vector. Biochemistry, 35, 2104-2111.
22. Mousli, M., Goyffon, M., and Billiald, P. (1998) Production and characterization of a bivalent single chain Fv/alkaline phosphatase conjugate specfic for the hemocyanin of the scorpion Androctonus australis. Biochim. Biophys. Acta 1425, 348-360.
23. Reiter, Y., and Pastan, I. (1996) Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin. Cancer Res. 2, 245-252.
24. Matthey, B., Engert, A., Klimka, A., Diehl, V., and Barth, S. (1999). A new series of pET-derived vectors for high efficiency expression of pseudomonas exotoxin-based fusion proteins. Gene 229, 145-153.
25. Francisco, J. A., Gawlak, S. L., Miller, M., Bathe, J., Russell, D., Chace, D., Mixan, B., Zhao, L., Fell, H. P., and Siegall, C. B. (1997) Expression and characterization of bryodin 1 and a bryodin 1-based single-chain immunotoxin from tobacco cell culture. Bioconjugate Chem. 8, 708-713.
26. Newton, D. L., Xue, Y., Olson, K. A., Fett, J. W., and Rybak, S. M. (1996) Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Biochemistry 35, 545-553.
27. Runge, M. S., Bode, C., Haber, E., and Quertermous, T. (1991) Hybrid molecules: insights into plasminogen activator function. Mol. Biol. Med. 8, 245-255.
28. Wallace, P. M., MacMaster, J. F., Smith, V. F., Kerr, D. E., Senter, P. D., and Cosand, W. L. (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorouracil. Cancer Res. 54, 2719-2723.
29. Aboagye, E. O., Artemov, D., Senter, P. D., and Bhujwalla, Z. M. (1998) Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res. 58, 4075-4078.
30. Bosslet, K., Czech, J., and Hoffman, D. (1994) Tumor-selective prodrug activation by fusion-protein-mediated catalysis. Cancer Res. 54, 2151-2159.